MNKD
MannKind Corporation
MNKD offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over MNKD overall, supported by stronger fundamentals and lower modeled downside.
MNKD Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Weak |
MNKD's revenue is currently strong, but its profitability, cash flow and balance sheet are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MNKD PE Valuation
MNKD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 178x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MNKD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect MNKD to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MNKD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | — |
| Q3 2026 | -$0.23 | -330% |
| Q2 2026 | -$0.13 | -218% |
| Q1 2026 | -$0.07 | -170% |
| Q4 2025 | $0.02 | -80% |
| Q3 2025 | $0.10 | +25% |
| Q2 2025 | $0.11 | +120% |
| Q1 2025 | $0.10 | +150% |
| Q4 2024 | $0.10 | +$0.14 |
MNKD has swung to a loss: it lost $0.23 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MNKD on earnings quality, reporting a profit while its opponent remains loss making.
MNKD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $101.9M | +24% |
| Q2 2026 | $109.4M | +43% |
| Q1 2026 | $90.2M | +15% |
| Q4 2025 | $112M | +46% |
| Q3 2025 | $82.1M | +17% |
| Q2 2025 | $76.5M | +5.7% |
| Q1 2025 | $78.4M | +18% |
| Q4 2024 | $76.8M | +31% |
MNKD's revenue has grown year over year for 17 quarters in a row: $102M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.1% | -25 points |
| Q2 2026 | -0.3% | -7.2 points |
| Q1 2026 | -1.9% | -30 points |
| Q4 2025 | -6.9% | -41 points |
| Q3 2025 | 23% | +4.8 points |
| Q2 2025 | 6.9% | -16 points |
| Q1 2025 | 28% | +3.2 points |
| Q4 2024 | 35% | +21 points |
MNKD's operating margin was −2.1% last quarter, down 25 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MNKD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MNKD on profitability, with a higher operating margin.
MNKD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.8M | -268% |
| Q2 2026 | -$23.5M | -399% |
| Q1 2026 | -$7.2M | -$538K |
| Q4 2025 | -$10M | -150% |
| Q3 2025 | $22.5M | +184% |
| Q2 2025 | $7.8M | +810% |
| Q1 2025 | -$6.7M | -256% |
| Q4 2024 | $19.7M | +25% |
MNKD has burned cash in most quarters: −$78M over the past year, against $43M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MNKD on cash generation, producing positive trailing cash flow while its opponent burns cash.
MNKD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +11M shares |
| 1 year | +2.7% | +8.5M shares |
| 3 years | -1.1% | -3.6M shares |
| 5 years | +28% | +70.3M shares |
| Available history | +55% | +113M shares |
MNKD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MNKD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 19.7x | High |
| Q2 2026 | 8.9x | High |
| Q1 2026 | 8.5x | High |
| Q4 2025 | 5.5x | High |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
MNKD's net debt is about 20 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MNKD on leverage, with a lower net debt burden relative to earnings.
MNKD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.4 | Neutral |
| Stochastic | 63.7 | Neutral |
MNKD's weekly RSI is 55 (neutral) and its Stochastic is 64 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MNKD PE vs Healthcare Sector
| Metric | MNKD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MNKD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MNKD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 18% above |
| 20 week MA | $3.82 | 8.9% above |
| 50 week MA | $4.00 | 4% above |
| 100 week MA | $4.48 | 7.1% below |
| 200 week MA | $4.62 | 10% below |
MNKD has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 10% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MNKD on trend strength, trading above more of its moving averages.
MNKD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.37 | $3.42 | +150% |
| 2021 | $3.42 | $4.46 | +30% |
| 2022 | $4.46 | $5.09 | +14% |
| 2023 | $5.09 | $3.64 | -28% |
| 2024 | $3.64 | $6.82 | +87% |
| 2025 | $6.82 | $5.79 | -15% |
| 2026 YTD | $5.79 | $4.16 | -28% |
MNKD has finished higher in four of the last six years, two of them by more than 50%. It's down 28% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MNKD on returns for 2026, with the stronger performance.